Major Research Areas

Selected Publications

Gregor PD, Wolchok JD, Ferrone CR, Buchinshky H, Guevara-Patino JA, Perales MA, Mortazavi F, Bacich D, Heston W, Latouche JB, Sadelain M, Allison JP, Scher HI, Houghton AN. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 2004 Apr 16;22(13-14):1700-8.

Solit DB, Scher HI, Rosen N. Hsp90 as a therapeutic target in prostate cancer. Semin Oncol. 2003 Oct;30(5):709-16.

Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke , Cordon-Cardo C, Pandolfi PP. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003 Dec;1(3):E59. Epub 2003 Oct 27.

Halabi S, Small EJ, Kantoff PW, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ. Prognostic model for predicting survival in men with hormone refractory metastatic prostate cancer. J Clin Oncol 2003; 21(7):1232-1237.

Kattan MW, Eastham JA. algorithms for PSA recurrence after treatment of localized prostate cancer. Clinical Prostate Cancer 2003;1:221-226.

Aleman M, Karakiewicz PI, Kupelian P, Kattan MW, Graefen M, Cagiannos I, Eastham J, Scardino PT, Huland H, Klein EA. Age and PSA predict the liklihood of organ-confined disease in men presenting with PSA < 10 Ng/M1: implications for screening. Urology 2003;62(1):70-4

Di Blasco C, Kattan MW. The use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer. Urology 2003;62:9-18.

Glinsky G, Glinskii A, Stephenson A, Hoffman R, Gerald W. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest. 2004;113:913-923

Stephenson A, Smith A, Kattan M, Satagopan J, Reuter V, Scardino P, Gerald W. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. Cancer. 2005;104(2):290-8

Chen Z, Trotman L, Shaffer D, Lin H, Dotan Z, Niki M, Koutcher J, Scher H, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi P. Critical role of p53 dependent cellular senesence in suppression of Pten deficient tumorgenesis. Nature. 2005;436:725-30

Shaffer D, Viale A, Ishiwata R, Leversha M, Olgac S, Manova K, Satagopan J, Scher HI, Koff A. Evidence for a p27 tumor suppression function independent of its role regulating cell proliferation in the prostate. Proc National Acad Sci USA. 2005;102:210-215.

Gregor PD, Wolchok JD, Turaga V, Latouche JB, Sadelain M, Bacich D, Heston W, Houghton AN, Scher HI. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer. 2005;116:415-21.

Guevara-Patino JA, Turk MJ, Wolchok JD, Houghton AN. Immunity to cancer through immune recognition of altered self: studies with melanoma. Adv in Cancer Res 2003;90:157-77.

Site Map \| Index	Legal Disclaimer \| Privacy Practices \| Public Notices

©2008 Memorial Sloan-Kettering Cancer Center. 212-639-2000 1275 York Avenue New York, NY 10065.	PublicAffairs@mskcc.org